Theranostics Health

med fusion, Pathologists Bio-Medical Laboratories (PBM) and Theranostics Health to Announce Availability of Novel Cancer Theranostic Test at ASCO

admin — Wed, 01 May 2013 15:32:13 +0000

Lewsiville, TX, May 1, 2013

med fusion, Pathologists Bio-Medical Laboratories (PBM) and Theranostics Health will be introducing the first of Theranostics Health’s TheraLink™ Assays for use in patients with malignant diseases at the upcoming American Society of Clinical Oncology (ASCO) Annual ’13 Meeting, held in Chicago, IL from May 30, 2013 through June 4, 2013.

TheraLink HER Family Assay – Press Release

Upcoming Events – 2013 ASCO Exhibitor

admin — Fri, 26 Apr 2013 14:17:16 +0000

ASCO Annual Meeting
Exhibit Hall – Booth 2056
McCormick Place, Chicago, IL
May 31 2013 to Jun 4 2013

Theranostics Health to Present at 8th Annual Mid-Atlantic BIO Conference

admin — Fri, 17 Aug 2012 18:45:33 +0000

Gaithersburg, MD, August 17, 2012. Theranostics Health, Inc., a privately-held biotechnology company seeking to develop proteomic-based personalized medicine technologies, announced today that Dr. Glenn Hoke (President and Chief Executive Office) will be presenting at the Emerging Growth track at the 2012 Mid-Atlantic BIO Conference in Bethesda, MD. Dr. Hoke will be providing an overview to potential investors into Theranostics Health’s scientific and business development efforts to commercialize Theranostics’ TheraLink™ Assays for use in patients with malignant diseases.

Mid-Atlantic BIO Investor Presentations

med fusion Partners with Theranostics Health to Advance Personalized Medicine for Patients with Cancer

admin — Thu, 16 Aug 2012 15:26:19 +0000

Lewsiville, TX, August 15, 2012

med fusion and Theranostics Health have entered into a Market Development Agreement to validate the clinical utility of Theranostics’ TheraLink™ Assays for use in patients with malignant diseases. The goal of this relationship is to help accelerate advancement of new methods in molecular diagnostics testing and their use in personalized predictive treatments.

med fusion Partners with Theranostics Health

Theranostics Health Obtains Combinatorial Therapy Diagnostic Patent

admin — Thu, 07 Jun 2012 14:36:14 +0000

Rockville, MD. june 6, 2012.

Theranostics Health Inc. announced today that the U.S. Patent and Trademark Office issued Patent Number 8,168,568 B1 entitled: “Combinatorial Therapy for Protein Signaling Diseases” on May 1, 2012. This patent is exclusively licensed to Theranostics Health from the Public Health Service. The claims of the patent cover methods for selecting combination therapies based upon the activation status of disease or cancer-related protein pathways, and will be the basis for a series of TheraLink™ Diagnostic Assays under development which will provide a proteomic-based approach to personalized medicine.

Press Release – Theranostics Health Combination Therapy Patent

Theranostics Health Launching Alternative to Formalin for Preserving Phosphoproteomic Tissue Samples.

admin — Mon, 17 Oct 2011 14:35:54 +0000

September 2, 2011. Proteomonitor.

http://www.genomeweb.com/proteomics/theranostics-health-launching-alternative-formalin-preserving-phosphoproteomic-t?page=2